Hypoallergenicity of an extensively hydrolyzed whey formula

Pediatric Allergy and Immunology - Tập 12 Số 2 - Trang 83-86 - 2001
P G Giampietro1, N I Kjellman2, Göran Oldaéus2, Wendeline Wouters‐Wesseling3, L Businco1
1Dept. of Paediatrics, University, ‘La Sapienza’, Rome, Italy
2Department of Health and Environment, Division of Paediatrics, Linköping University, Linköping, Sweden,
3Numico Research, Wageningen, The Netherlands

Tóm tắt

Several different protein hydrolysate‐based infant formulas have been promoted as hypoallergenic and considered suitable for the dietary management of cow's milk allergy (CMA). Accepting that none of the hydrolysate‐based products is completely safe, the American Academy of Pediatrics (AAP) recommends that these formulas should be tested in a double‐blind placebo‐controlled setting and tolerated by at least 90% of children with proven CMA. In principle, this recommendation is also endorsed by the European Society of Paediatric Gastroenterology and Nutrition (ESPGAN) and the European Society of Paediatric Allergy and Clinical Immunology (ESPACI). In this two‐center study, 32 children with proven CMA were tested with the extensive hydrolysate whey formula Nutrilon Pepti, for comparison with Profylac (extensive) and Nan HA (partial) whey hydrolysate products. Skin‐prick tests (SPTs) were, respectively, positive to the three hydrolysate formulas in 19%, 15%, and 32% of children. After oral challenge it was concluded that 97% (95% CI: 85–100%) of the children tolerated Nutrilon Pepti, 94% (95% CI: 75–100%) tolerated Profylac, and 64% (95% CI: 37–81%) tolerated Nan HA. This study demonstrates that the extensive hydrolysates Nutrilon Pepti and Profylac are well tolerated in a population of children with proven CMA and that both products can be considered safe for their intended use. This study confirms that a very small number of children react even to extensively hydrolyzed formulas. SPT prior to oral exposure to the hydrolysate‐based formulas can indicate whether a child is at risk of showing reactions to the product. Introduction of new products to these children should be carried out under a doctor's supervision. However, the majority of the SPT‐positive children did tolerate the two extensively hydrolyzed whey‐based formulas tested.

Từ khóa


Tài liệu tham khảo

Kleinman RE, 1990, Infant Formulas and Allergic Disease. FDA Report: 223‐86‐2117.

10.1111/j.1399-3038.1991.tb00200.x

Aggett PJ, 1993, Comment on antigen‐reduced infant formulae, Acta Paediatr, 82, 314, 10.1111/j.1651-2227.1993.tb12821.x

10.1111/j.1399-3038.1993.tb00077.x

10.1111/j.1399-3038.1994.tb00237.x

Verwimp JJM, 1993, Efficiency of whey protein hydrolysate based infant formulas in infants with cow's milk protein allergy, Allergy, 48, S113

Verwimp JJM, 1995, Symptomatology and growth in infants with cow's milk protein intolerance using two different whey‐protein hydrolysate based formulas in a Primary Health Care setting, Eur J Clin Nutr, 49, S39

Barents M, 1993, Diagnosis and treatment of cow's milk protein allergy in a baby health clinic setting: the feas‐ibility of a standardized approach, Allergy, 48, S113

10.1097/00005176-199307000-00014

10.1177/000992289303200708

10.1111/j.1651-2227.1994.tb13370.x

10.1111/j.1398-9995.1993.tb04756.x

10.1007/BF01953996

10.1111/j.1399-3038.1993.tb00067.x

10.1016/S0022-3476(05)90001-2

10.1111/j.1399-3038.1991.tb00201.x

10.1016/S0091-6749(06)80023-0

10.1111/j.1365-2222.1992.tb00180.x

10.1016/S0022-3476(05)81412-X

10.1097/00005176-199804000-00007

Thông tin
Thông tin xuất bản

Pediatric Allergy and Immunology

Tập 12 Số 2

83-86

Thông tin tác giả